Table 1.
Parameter estimates for linear latent growth models for opioid-positive samples at baseline and 4 weeks of treatment
| Independent variable | Dependent variable | Unstandardized estimate (B) | 95% CI | P-value | |
|---|---|---|---|---|---|
| Model 1: Total sample |
|||||
| --- | UA intercept | .53 | −1.26, 2.32 | .56 | |
| --- | UA slope | .77 | .19, 1.25 | .01 | |
| Sex | UA intercept | −1.18 | −1.22, −.21 | .02 | |
| Trial arm | UA intercept | .35 | −.14, .85 | .16 | |
| Age (years) | UA intercept | −.04 | −.08, .002 | .06 | |
| Trial arm*sex | UA intercept | .70 | .17, 1.23 | 01 | |
| Sex | UA slope | .33 | .09, .58 | .01 | |
| Trial arm | UA slope | −.23 | −.35, −.10 | <.001 | |
| Age (years) | UA slope | −.003 | −.01, .01 | .64 | |
| Trial arm*sex | UA slope | −.11 | −.25, .02 | .12 | |
| UA intercept | UA slope | −.12 | −.19, −.05 | .001 |
Buprenorphine/naloxone tapering groups were coded as −.5 = 7-day taper group (referent group), .5 = 28-day taper group, and sex was coded as −.5 = male (referent group), .5 = female; ASI-L composite scores were grand-mean centered.